Skip to main content
NIH funding notice RFA-DA-25-060

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)

Open. Closes March 5, 2027.

Posted
January 17, 2024
Close date
March 5, 2027
Activity codes
RM1
Institutes taking part
NIDA

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page names no earlier notice: it is new, or it does not say.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,301,614 in first-year total cost, median $2,150,807.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 TXT-E (J1)]2

Most frequent institutions

  1. NORTHERN CALIFORNIA INSTITUTE/RES/EDU1
  2. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
Competing awards under RFA-DA-25-060 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025In Vivo Imaging and Post-Mortem Study of Methamphetamine Use on Immune Dysfunction and HIV Reservoir Transcription among People with HIV on ART1RM1DA063218-01DEITCHMAN, AMELIA NHENRICH, TIMOTHY JENSENLEE, SULGGI ANGELATSENG, ZIAN HVANBROCKLIN, HENRY F.UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$2,331,737ZDA1
2025Stimulant and Polysubstance use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE)1RM1DA063351-01AOUIZERAT, BRADLEY EHUNT, PETER WKIZER, JORGE RRILEY, ELISE D.TIEN, PHYLLIS CWU, KATHERINE CNORTHERN CALIFORNIA INSTITUTE/RES/EDU, CA$1,969,877ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-25-060: High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) | ScienceDex | ConductScience